Actuate Therapeutics, Inc. (NASDAQ: ACTU)

Sector: Healthcare Industry: Biotechnology CIK: 0001652935
P/B 14.87
P/E -6.74
P/S 0.00
Market Cap 162.66 Mn
ROIC (Qtr) -588.37
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00

About

Stock Price Chart

Analysis

Pros

  • Cash reserves of 16.92M provide solid 41.79x coverage of other non-current liabilities 404991, indicating strong liquidity.
  • Cash reserves of 16.92M provide robust 2.66x coverage of current liabilities 6.37M, indicating strong short-term solvency.
  • Strong cash position of 16.92M provides 3.58x coverage of other current liabilities 4.72M, indicating excellent liquidity.
  • Cash position of 16.92M represents healthy 1.53x of working capital 11.07M, demonstrating strong operational liquidity.
  • Robust R&D investment of 11.85M at 0.95x of SG&A 12.52M demonstrates strong commitment to innovation and future growth.

Cons

  • Investment activities of 0 provide weak support for R&D spending of 11.85M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (20.24M) shows concerning coverage of stock compensation expenses of 5.70M, with a -3.55 ratio indicating potential earnings quality issues.
  • High financing cash flow of 23.64M relative to working capital of 11.07M, which is 2.14x suggests concerning dependence on external funding for operational needs.
  • Operating cash flow of (20.24M) is outpaced by equity issuance of 24.03M (-0.84 ratio), indicating concerning reliance on equity markets for funding operations.
  • Tangible assets of 17.71M provide limited backing for working capital of 11.07M, which is 1.60x, suggesting increased operational risk in market downturns.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 8.82 12.31
EV to Cash from Ops. -7.71 23.25
EV to Debt 0.00 738.44
EV to EBIT -6.48 -9.16
EV to EBITDA -6.41 6.95
EV to Free Cash Flow [EV/FCF] -7.71 21.90
EV to Market Cap 0.96 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 14.87 22.34
Price to Earnings [P/E] -6.74 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage -1,189.29 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 0.00 -27.13
Cash and Equivalents Growth (1y) % 25.15 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % 15.24 -46.93
EBITDA Growth (1y) % 7.06 -1.68
EBIT Growth (1y) % 15.24 -56.45
EBT Growth (1y) % 15.22 -12.70
EPS Growth (1y) % 102.29 -28.31
FCF Growth (1y) % 10.36 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 2.66 3.85
Current Ratio 2.74 7.27
Debt to Equity Ratio 0.00 0.40
Interest Cover Ratio -1,189.29 841.00
Times Interest Earned -1,189.29 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22